Schock, Lisa
Chmielewski, Witold X.
Siegel, Sonja
Detomas, Mario
Deutschbein, Timo
Giese, Sabrina
Honegger, Jürgen
Unger, Nicole
Kreitschmann-Andermahr, Ilonka
Funding for this research was provided by:
Ipsen Pharma GmbH München, Germany
Article History
Received: 1 February 2024
Accepted: 29 March 2024
First Online: 13 April 2024
Compliance with ethical standards
:
: I.K.-A., N.U. and J.H. received research and/or travel grants and/or speaker’s/advisory board honoraria from companies producing acromegaly medications, i.e. IPSEN Pharma GmbH, Germany; Pfizer Pharma; Recordati Rare Diseases Germany GmbH, Advanz Pharma GmbH. M.D. received travel grants from IPSEN. T.D. received travel grants from Recordati Rare Diseases Germany GmbH and Advanz Pharma GmbH. The other authors report no competing interests.
: All patients included in the analysis provided written informed consent.
: The study was approved by the local ethics committee of the University Hospital of Essen (17-7650-BO) and was conducted according to the Declaration of Helsinki.